Our results showed that patients with lower OpiHi monocyte scores were found to have a favorable response to anti-TNF treatment, suggesting that the OpiHi monocyte score may be a reliable model to assess IBD patient eligibility for anti-TNF therapy. The gene discussed is TNF; the disease is inflammatory bowel disease.